Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies

Neurology

Volumn 47, Issue 2, 1996, Pages 425-432

  McGeer, Patrick L ^a   Schulzer, Michael ^a   McGeer, Edith G ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; DAPSONE; HISTAMINE H2 RECEPTOR ANTAGONIST; NONSTEROID ANTIINFLAMMATORY AGENT;

ALZHEIMER DISEASE; ARTHRITIS; ARTICLE; INFLAMMATION; META ANALYSIS; NERVE INJURY; PRIORITY JOURNAL; RISK FACTOR; STATISTICAL ANALYSIS;

EID: 0029811901     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.47.2.425     Document Type: Article

References (38)

1. McGeer PL, Rogers J, McGeer EG. Neuroimmune mechanisms in Alzheimer disease pathogenesis. Alzheimer Dis Assoc Disord 1994;8:149-165.
2. McGeer PL, McGeer EG. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Rev 1995;21:195-218.
3. McGeer PL, Rogers J. Anti-inflammatory agents as a therapeutic approach to Alzheimer's disease. Neurology 1992;42: 447-449.
4. McGeer PL, McGeer EG, Rogers J, Sibley J. Anti-inflammatory drugs and Alzheimer disease. Lancet 1990;335: 1037.
5. Heyman A, Wilkinson WE, Stafford JA, Helms MJ, Sigmon AH, Weinberg T. Alzheimer's disease: a study of epidemiological aspects. Ann Neurol 1984;15:335-341.
6. French LR, Schuman LM, Mortimer JA, Hutton JT, Boatman RA, Christians B. A case-control study of dementia of the Alzheimer's type. Am J Epidemiol 1985;121:414-421.
7. Broe GA, Henderson AS, Creasey H, et al. A case-control study of Alzheimer's disease in Australia. Neurology 1990;40: 1698-1707.
8. Breteler MMB, van Duijn CM, Andra VCI, et al. Medical history and the risk of Alzheimer's disease: a collaborative reanalysis of case-control studies. Int J Epidemiol 1991;20:S36-S42.
9. Li G, Shen YC, Chen CH, Zhau YW, Silverman JM. A case-control study of Alzheimer's disease in China. Neurology 1992; 42:1481-1482.
10. Anon. Canadian Study of Health and Aging: Risk factors for Alzheimer's disease in Canada. Neurology 1994;44:2073-2080.
11. Breitner JCS, Gau BA, Welsh KA, et al. Inverse association of anti-inflammatory treatments and Alzheimer's disease. Neurology 1994;44:227-232.
12. Breitner JCS, Welsh KA, Helms MJ, et al. Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol Aging 1995;16;523-530.
13. Graves AB, White E, Koepsell TD, et al. A case-control study of Alzheimer's disease. Ann Neurol 1990;28:766-774.
14. Jenkinson MI, Bliss MR, Brain AT, Scott DL. Rheumatoid arthritis and senile dementia of the Alzheimer's type. Br J Rheumatol 1989;28:86-87.
15. Beard CM, Kokmen E, Kurland LT. Rheumatoid arthritis and susceptibility to Alzheimer's disease. Lancet 1991;337:1426.
16. Myllykangas-Luosujarvi R, Isomaki H. Alzheimer's disease and rheumatoid arthritis. Br J Rheumatol 1994;33:501-502.
17. Lucca U, Tettamanti M, Forloni G, Spagnoli A. Nonsteroidal anti-inflammatory drug use in Alzheimer's disease. Biol Psychiatry 1994;36:854-856.
18. Andersen K, Launer LJ, Ott A, Hoes AW, Breteler MMB, Hofman A. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? Neurology 1995;45:1441-1445.
19. Rich JB, Rasmusson DX, Folstein MF, Carson KA, Kawas C, Brandt J. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology 1995;45:51-55.
20. McGeer PL, Harada N, Kimura H, McGeer EG, Schulzer M. Prevalence of dementia amongst elderly Japanese with leprosy: apparent effect of chronic drug therapy. Dementia 1992; 3:146-149.
21. Fleiss JL. Statistical methods for rates and proportions. 2nd ed. New York: John Wiley & Sons, 1981:160-176.
22. Fleiss JL. Measures of effect size for categorical data. In: Cooper H, Hedges LV, eds. The handbook of research synthesis. New York: Russell Sage Foundation, 1994;245-260.
23. Shadish WR, Haddock CK. Combining estimates of effect size. In: Cooper H, Hedges LV, eds. The handbook of research synthesis, New York; Russell Sage Foundation, 1994:261-281.
24. Hedges LV, Olkin I. Statistical methods for meta-analysis. San Diego: Academic Press, 1985:107-145, 189-203, 285-309.
25. Rosenthal R. The "file drawer" problem and tolerance for null results. Psychol Bull 1979;86:638-641.
26. Begg CB. Publication bias. In: Cooper H, Hedges LV, eds. The handbook of research synthesis. New York: Russell Sage Foundation, 1994:399-409.
27. Anon. Canadian Study of Health and Aging: study methods and prevalence of dementia. Can Med Assoc J 1994;150:899-913.
28. Corrada M, Stewart W, Kawas C. Nonsteroidal anti-inflammatory drugs and the risk of Alzheimer's disease. Neurology 1996;46:A433.
29. Landfield PW, Eldridge JC. Increased affinity of type II corticosteroid binding in aged rat hippocampus. Exp Neurol 1989; 106:110-113.
30. Lewis DA, Smith RE. Steroid-induced psychiatric syndromes. J Affect Disord 1983;5:319-332.
31. Graham DY, AgrawaL NM, Roth SH. Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial. Lancet 1988;2:1277-1280.
32. Zuidema J, Hilbers-Modderman ESM, Merkus FWHM. Clinical pharmacokinetics of dapsone. Clin Pharmacokinet 1986; 11:299-315.
33. Lindskov R, Reymann F. Dapsone in the treatment of cutaneous lupus erythematosus. Dermatoiogia 1986;172:214-217.
34. Boesen P, Dideriksen K, Stenoft J, Jensen MK. Dapsone in temporal arteritis and polymyalgia rheumatica. J Rheumatol 1988;15:879-880.
35. Sharquie KE. Suppression of Behçet's disease with dapsone. Br J Dermatol 1984;110:493-494.
36. Guillebin L. Treatment of polyarteritis nodosa with dapsone. Scand J Rheumatol 1986;15:95-96.
37. Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993;43: 1609-1611.
38. Mortimer JA, Ebbitt B, Jun S-P, Finch MD. Predictors of cognitive and functional progression in patients with probable Alzheimer's disease. Neurology 1992;42:1689-1696.